MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of ...

NEW YORK--(BUSINESS WIRE)--Massive Bio today announced it has entered a partnership with Veterans Prostate Cancer Awareness (VPCa), and Self-Care Catalysts to increase clinical trial and real-world ...

MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro ...

Cancer trial matchmaker Massive Bio is teaming up with two organizations to boost clinical studies and research participation for prostate cancer. Massive Bio, Veterans Prostate Cancer Awareness and ...

• Applications of germline genetic testing, tumor genomics, and other biomarkers are now routinely used in risk assessment, determination of treatment course, prognosis, and monitoring. • Imaging ...

A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...

While prostate cancer affects one in eight men, early detection and advanced treatment options mean patients are living longer, healthier lives after diagnosis, according to the American Cancer ...